Blood Research and EnhAnced Training against HIV in South Africa (BREATH-SA)

续签加州大学旧金山分校(UCSF)/维他命研究所(VRI)，大学 开普敦(UCT)和南非国家血液服务中心(SANBS)的血液研究和增强 南非抗艾滋病毒培训(呼吸-SA)计划将培训血液学家和血液银行家 进行高质量的艾滋病毒研究，以解决南非的相关研究问题。南非需要 HIV流行对HIV相关血液病及国民血液影响的研究进展 供给。这项建议建立在国家统计局和国家统计局之间长达22年的艾滋病毒研究合作历史的基础上 UCSF/VRI以及在NHLBI资助的REDS-III国际艾滋病毒下与UCT建立的为期10年的研究伙伴关系 研究网络。我们计划的头五年在过去的五年中取得了实质性进展 在SANBS和UCT建设研究能力的具体目标，提供大量培训活动，毕业 13名硕士和博士生，并取得了强劲的出版记录。然而，我们最新的需求 评估表明，更好的职业支持，更多的指导和更多的历史接触 需要弱势机构来实现我们的总体目标，即创建可持续的 在南非优秀的艾滋病毒相关输血医学和血液学研究企业。为了这个 更新，我们提出了这些具体目标：1)培养下一代艾滋病毒血液学临床研究人员 和输血医学将成为独立的研究人员，他们将在#年应对新的健康挑战 这些领域；2)加强国家统计局研究和应用艾滋病毒研究的机构研究能力 发展学院以及UCT血液科的临床和转化性艾滋病毒研究；以及3) 建立南非艾滋病毒血液学和输血医学卓越中心 历史上处于不利地位的机构和解决研究机会不平等问题。我们计划一个四层的 各级受训人员的教育方法：临床研究方法学的国内短期课程， 方案设计和手稿准备将提供给大量受训人员；对于缺乏的较少人数 研究设计、生物统计学和数据分析方面的技能我们建议在开普敦和 旧金山；对于最有希望的人，UCT卫生学院的硕士和博士学位招生 理科；对于该项目的毕业生，一个新的早期阶段调查员级别，提供职业指导和 大刀阔斧训练。所有学员将在完成研究项目、竞争迷你- 由该计划资助的赠款并出版手稿。研究资源包括艾滋病毒淋巴瘤登记处 和临床资源，来自REDS-III HIV研究网络的存档数据和样本，以及REAL-III-HIV研究网络和真正的- 为血液中心的艾滋病毒检测数据计时。高影响力研究课题包括：艾滋病毒淋巴瘤生物学、临床 病程和治疗；艾滋病毒相关贫血和恶性肿瘤；使用新实验室的艾滋病毒流行率和发病率 艾滋病毒检测；抗逆转录病毒治疗对艾滋病毒检测的影响；以及艾滋病毒患者的适当输血治疗。

The renewal of the University of California San Francisco (UCSF)/Vitalant Research Institute (VRI), University of Cape Town (UCT) and South Africa National Blood Service (SANBS) Blood Research and EnhAnced Training against HIV in South Africa (BREATH-SA) program will train hematologists and blood bankers to perform high-quality HIV research to address relevant research questions in South Africa. South Africa needs ongoing research on its HIV epidemic’s impact on HIV-related hematologic diseases and the national blood supply. This proposal builds upon a 22-year history of HIV research collaboration between SANBS and UCSF/VRI and a 10-year research partnership with UCT under the NHLBI-funded REDS-III International HIV research network. The first five years of our program have made substantial progress towards our previous specific aims of building research capacity at SANBS and UCT, offering numerous training activities, graduating 13 Master’s and PhD students and achieving a robust publications record. However, our updated needs assessment has indicated that better career support, increased mentoring and more outreach to historically disadvantaged institutions is needed to achieve our overarching goal of creating sustainable centers of excellence in HIV-related transfusion medicine and hematology research enterprise in South Africa. For this renewal, we propose these Specific Aims: 1) Train the next generation of clinical researchers in HIV hematology and transfusion medicine to become independent researchers who will address emerging health challenges in these areas; 2) Strengthen institutional research capacity in applied HIV research at the SANBS Research and Development Academy and clinical and translational HIV research at the UCT Haematology Division; and 3) Develop a South African center of excellence in HIV hematology and transfusion medicine that will reach out to historically disadvantaged institutions and address inequities in research opportunity. We plan a four-tiered educational approach for trainees at various levels: in-country short courses on clinical research methodology, protocol design and manuscript preparation will reach a large number of trainees; for a smaller number lacking skills in study design, biostatistics and data analysis we propose medium-term course work in Cape Town and San Francisco; for the most promising, Master’s and PhD degree enrollment at the UCT School of Health Sciences; and for graduates of the program, a new early-stage investigator tier providing career mentorship and grantsmanship training. All trainees will be mentored as they accomplish research projects, compete for mini- grants funded by the program and publish manuscripts. Research resources include the HIV lymphoma registry and clinical resources at UCT, archived data and specimens from the REDS-III HIV research network and real- time HIV testing data from blood centers. High impact research topics include: HIV lymphoma biology, clinical course and treatment; HIV-related anemias and malignancies; HIV prevalence and incidence using novel lab assays; antiretroviral therapy’s impact on HIV testing; and appropriate transfusion therapy for HIV patients.